Zain Habboo, co‑founder of the Rakan Stormer Research Fund, writes from personal tragedy to warn that federal support for childhood cancer is eroding. Her son Rakan died in 2025 from a rare Wilms’s tumor after a year of intensive treatment. The essay notes that pediatric oncology receives only single‑digit percentages of overall cancer research dollars, leaving thousands of young patients without cutting‑edge trials.

During the Trump administration, the 26‑year‑old Pediatric Brain Tumor Consortium lost its funding authorisation in March, ending a critical pathway for experimental pediatric trials. The following month the president’s 2027 budget proposed a 12 percent reduction to the National Institutes of Health, and NIH officials report that the National Cancer Institute has allocated less than one‑third of its usual grant budget for the year.

Habboo argues that these incremental cuts amount to a “death by a thousand cuts,” threatening ongoing trials and prompting layoffs that drain institutional knowledge. With roughly 15,000 American children diagnosed annually, the loss of federal dollars translates into fewer therapeutic options and higher mortality. Restoring the budget would reopen closed studies and re‑enable the pipeline that once made U.S. oncology research a global benchmark.